10 & 11 February – Cancer Biology & the Science of Targeted Treatments

Monday & Tuesday 10-11 February 2014, London

2-day course: Cancer Biology & the Science of Targeted Treatments

Level: intermediate/advanced (Designed for research nurses and clinical trials staff with at least some understanding of cell biology.)

Description: This 2-day course provides a grounding in cancer biology before moving to descriptions of a wide range of targeted treatments for solid tumours and haematological cancers. Also includes mechanisms of drug resistance and an introduction to biomarkers and personalised cancer care. This course includes a variety of practical exercises, question sheets and quizzes.

To book, contact: Veronica Sinclair (this course is organised by the NCRN)

Programme Day 1

Cancer cell biology – key concepts
  • Cells, DNA, chromosomes, genes, proteins
  • Cell division and the cell cycle
  • Causes of DNA damage
  • Oncogenes and tumour suppressor genes
The hallmarks of cancer
  • 8 hallmarks of cancer cells
  • The tumour microenvironment

Hallmarks of cancer: practical exercise

Introduction to targeted cancer treatments
  • The current state of play of targeted cancer treatments
  • Monoclonal antibodies and small molecule inhibitors
  • Mechanisms of action, specificity and side effects – comparing monoclonal antibodies and small molecules
Specific treatments for haematological cancers
  • Monoclonal antibodies for leukaemia and lymphoma
  • Bcr-Abl inhibitors
Why the drugs don’t work
  • The complexity of cancer
  • Genetic instability and intratumoural heterogeneity
  • Resistance mechanisms

Programme Day 2

Targeted treatments for solid tumours part 1
  • The importance of receptor tyrosine kinases (RTKs) and their downstream pathways as drug targets for solid tumours
  • RTK inhibitors in use and trials
  • mTOR and B-Raf inhibitors
  • Un-druggable targets
Targeted treatments for solid tumours part 2
  • VEGF/angiogenesis inhibitors
  • PARP inhibitors
  • ALK inhibitors

Clinical trials speed dating

Targeted treatments for solid tumours part 3
  • HSP90 inhibitors
  • Hedgehog pathway inhibitors
  • Immunotherapy
Clinical trials for targeted treatments: a moving picture
  • New paradigms in clinical trial design
  • Clinical development case studies: gefitinib and crizotinib
  • The use of biomarkers to select patients for trials and treatments for patients

Novel agents: practical exercise